DAX24.324 +0,2%ESt505.411 +0,1%Top 10 Crypto13,39 -1,3%Dow42.320 -0,3%Nas19.298 -0,8%Bitcoin90.217 +1,6%Euro1,1435 -0,1%Öl65,24 -0,1%Gold3.360 +0,2%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 Tesla A1CX3T RENK RENK73 NVIDIA 918422 HENSOLDT HAG000 Bayer BAY001 Lufthansa 823212 Siemens Energy ENER6Y BioNTech (ADRs) A2PSR2 BYD A0M4W9 Infineon 623100 Commerzbank CBK100 BASF BASF11 Deutsche Bank 514000 Deutsche Telekom 555750
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-Arbeitsmarkt im Fokus: DAX stabil erwartet -- Asiens Börsen uneinheitlich -- Broadcom enttäuscht trotz Gewinnsprung -- Tesla-Aktie bricht nach Streit von Musk und Trump ein -- VW im Fokus
Top News
Nach Bilanzvorlage: Wieso Morgan Stanley nun doch von der Reddit-Aktie überzeugt ist Nach Bilanzvorlage: Wieso Morgan Stanley nun doch von der Reddit-Aktie überzeugt ist
Vor US-Arbeitsmarktbericht: DAX nach jüngstem Rekordhoch mit leichten Abgaben erwartet Vor US-Arbeitsmarktbericht: DAX nach jüngstem Rekordhoch mit leichten Abgaben erwartet
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
FONDSPREMIERE: BIT Capital legt ersten Multi-Asset-Fonds auf

Aesculap Introduces XABO® Antibiotic-Impregnated Catheters for Hydrocephalus Treatment

04.06.25 15:36 Uhr

CENTER VALLEY, Pa., June 4, 2025 /PRNewswire/ -- Aesculap, Inc. (Aesculap), the world's largest manufacturer of surgical instruments known for its innovations in neurosurgery, power systems and visualization, has launched XABO® Antibiotic-Impregnated Catheters in the U.S. market which will help to significantly reduce the risk of shunt infections in hydrocephalus patients.1 This innovative product is designed to improve treatment for both pediatric and adult patients who suffer from this condition.

Aesculap logo (PRNewsfoto/Aesculap, Inc.)

Hydrocephalus, characterized by excessive cerebrospinal fluid in the brain, affects over 1 million people in the United States. Shunt therapy, the most common treatment,2 often comes with the risk of infection,3 which impacts 7-15% of patients.4 These infections can impair quality of life, cognitive function and shunt survival.5

The XABO Antibiotic-Impregnated Catheters offer enhanced infection control, with clinical studies showing a two-thirds reduction in shunt infection rates as compared to standard catheters.4 The catheters continuously release antibiotics for a minimum of 38 days post-implantation,6 covering the critical period when patients are most vulnerable to infections.3,8-10 The XABO Antibiotic-Impregnated Catheter's unique packaging allows for extended sterility, up to 36 months, as well as being able to withstand temperatures up to 86°F without losing their effectiveness.6 The high potency of clindamycin hydrochloride and rifampicin impregnation allows for low antibiotic dosage release which may reduce allergic reactions and minimize the risk of resistance development.

"We are excited to introduce the XABO Antibiotic-Impregnated Catheters, which represent a significant advancement in the treatment of hydrocephalus," said Bob Sowinski, Corporate Vice President, Aesculap. "This launch is key to our goal to improve patient outcomes and quality of life by reducing the incidence of shunt infections, a common and serious complication of hydrocephalus treatment."

For more information, please visit our website.

About Aesculap, Inc.

Aesculap, Inc., a B. Braun company, is part of a 180-year-old global organization focused on meeting the needs of an ever-changing healthcare community. Through close collaboration with its customers, Aesculap provides advanced technologies for neurosurgery, general surgery and sterilization technologies. Aesculap continues a proud heritage of leadership and responsiveness as we strive to deliver products and services that improve the quality of patients' lives. For more information, call 800-282-9000 or visit aesculapusa.com.

References:

  • Fernández-Méndez R, Richards HK, Seeley HM, et al. Current epidemiology of cerebrospinal fluid shunt surgery in the UK and Ireland (2004-2013).
  • Hydrocephalus Association. (2021). What is Hydrocephalus? | Hydrocephalus Association. www.hydroassoc.org. https://www.hydroassoc.org/about-hydrocephalus/ 2. Okamura Y, Maruyama K, Fukuda S, et al. Detailed standardized protocol to prevent cerebrospinal fluid shunt infection. J Neurosurg 2019:1–5.
  • Okamura Y, Maruyama K, Fukuda S, et al. Detailed standardized protocol to prevent cerebrospinal fluid shunt infection. J Neurosurg 2019:1–5.
  • Fernández-Méndez R, Richards HK, Seeley HM, et al. Current epidemiology of cerebrospinal fluid shunt surgery in the UK and Ireland (2004-2013).
  • Vinchon M, Dhellemmes P. Cerebrospinal fluid shunt infection: risk factors and long-term follow-up. Childs Nerv Syst 2006;22(7):692–97.
  • MIETHKE report. Data on file.
  • Okamura Y, Maruyama K, Fukuda S, et al. Detailed standardized protocol to prevent cerebrospinal fluid shunt infection. J Neurosurg 2019:1–5.
  • Borgbjerg BM, Gjerris F, Albeck MJ, Børgesen SE. Risk of infection after cerebrospinal fluid shunt: an analysis of 884 first-time shunts. Acta Neurochir (Wien). 1995;136(1-2):1-7.
  • George R, Leibrock L, Epstein M. Long-term analysis of cerebrospinal fluid shunt infections. A 25-year experience. J Neurosurg. 1979;51(6):804-811.
  • Wells DL, Allen JM. Ventriculoperitoneal shunt infections in adult patients. AACN Adv Crit Care. 2013;24(1):6-14.

    • Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/aesculap-introduces-xabo-antibiotic-impregnated-catheters-for-hydrocephalus-treatment-302473172.html

    SOURCE Aesculap, Inc.